Moderna's stock surged on Monday after the biotechnology company confirmed it would release highly anticipated Phase III data for its experimental mRNA cancer vaccine next month. The vaccine is being tested in combination with Merck's immunotherapy drug Keytruda for patients with advanced melanoma who have undergone surgery. The two companies had already announced preliminary results in August, showing the late-stage trial met its primary endpoint.